



Global News and Announcements

Overview

A huge thank you to all our NCIs who have helped and provided solid support throughout Cohort 2—much appreciated. As we are approaching our 10,000 target—we are gearing up for exciting new ventures in the near future. We are also currently looking into the feasibility of a meeting in Mexico City for our Latin American sites, possibly later in the year.



Recruitment

Cohort 2 recruitment is progressing very well and ahead of our projections—all thanks to you. To date, we have recruited 8,878 patients. We have recruited 89% of our target and we kindly please ask you to continue to encourage the investigational sites in your country so as to not slow down in this summer period because it is a crucial period in recruitment

Thank you....

June has been a busy month with lots of logistics being worked on, future plans discussed, in addition to processing the June site payments. We appreciated your help in encouraging the sites in your respective country to complete the data cleaning in time for this milestone.

Overall Study Status at a Glance

No. of patients recruited : 8878
 No. of sites selected (actual/planned): 477/490
 No. of sites initiated: 425
 No. of recruiting sites: 391

TRI is also working on another important piece of research , please click below :


FIND OUT ABOUT THE SURVEY NOW

Frontline2 is a global survey, funded by an unrestricted grant from Bayer Pharma AG. The survey will collate the views of oncologists, haematologists, surgeons, radiation oncologists and members of the palliative care team who are responsible for treating cancer-associated thrombosis.

The aim of this research is to describe the evolution of clinical understanding in the field of cancer associated thrombosis since the first FRONTLINE study in 2001, and to highlight variations in care.

Country Highlights

GARFIELD-VTE – Recruitment in Canada



www.tri-london.ac.uk



Sites selected	13
EC submissions completed	12
EC/Regulatory approvals in place	12
Clinical Trial Agreements fully executed	12
Site Initiation Visits completed	12
Patients enrolled	465

Project Team at TRI

Gloria Kayani (Chief Operating Officer), Elizabeth Demmisse (Regional Project Manager), Saba Salman (Regional Project Manager), Luz Angela Gomez (Clinical Trial Administrator).



Site Regulatory Start-up

PI Name	Site #	SIV	Projection during IMVs	Expected Enrolment to date	Actual Enrolment per EDC
Erdelyi, Barbara	CAN0075	21-Jan-15	10	8	0
Datta, Sudip	CAN0069	5-Nov-14	12	10	4
Zidel, Brian	CAN0100	14-Jan-15	16	14	1
Carrier, Marc	CAN0232	25-Feb-15	152	128	169
Solymoss, Susan	CAN0233	27-Apr-15	41	34	45
Le Gal, Gregoire	CAN0370	18-Sep-15	36	27	32
Kelly, Allan	CAN0379	13-Oct-15	18	13	2
Poirier, Germain	CAN0397	15-Jul-15	25	20	7
Ayala-Paredes, Félix	CAN0402	27-Aug-15	15	12	8
Kassis, Jeannine	CAN0403	8-Oct-15	31	23	10
Wu, Cynthia	CAN0460	14-Apr-16	100	45	8
Yeo, Erik	CAN0461	22-Apr-16	25	11	4
Kovacs, Michael	CAN1004	23-Mar-15	175	146	175

To find out more about Frontline2 please click below :



Frontline2
FIND OUT ABOUT THE SURVEY NOW

Frontline2 is a global survey, funded by an unrestricted grant from Bayer Pharma AG. The survey will collate the views of oncologists, haematologists, surgeons, radiation oncologists and members of the palliative care team who are responsible for treating cancer-associated thrombosis.

frontline2.tri-london.ac.uk

TRI Thrombosis Research Institute

The aim of this research is to describe the evolution of clinical understanding in the field of cancer associated thrombosis since the first FRONTLINE study in 2001, and to highlight variations in care, nationally and internationally.

